Pushkal Garg; Chief Medical Officer, Executive Vice President - Development and Medical Affairs; Alnylam Pharmaceuticals Inc Jeffrey Poulton; Chief Financial Officer, Executive Vice President; Alnylam ...

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and ...

BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2024 ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and ...

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (SLN – Research Report) and keeping the price ...

PORTLAND, IN, UNITED STATES, January 28, 2025 /EINPresswire / -- The RNA based therapeutics has been explored as a promising treatment option for the diseases which are difficult to treat. Development ...

The failure of each of these key individuals to come and answer questions under oath spoke volumes in itself, but their collective silence is deafening. Today's result has been achieved only ...

The plot thickens in the messy legal battle between Blake Lively and Justin Baldoni, which began after the release of their film It Ends With Us. While both sides have accused the other of bad ...

bDepartment of Neurological Surgery, Malnati Brain Tumor Institute of the Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA cDepartment ...